Back to search
FDAFDA · Food and drugs·Recall number Z-0083-2014

Valiant Thoracic Stent Graft with Captivia Delivery System, Talent Thoracic Stent Graft with the Captivia Delivery System.

Published November 6, 2013 · Recall initiated: September 19, 2012

Summary

FDA records medical device Class II recall Z-0083-2014, published November 6, 2013 and initiated September 19, 2012. Recalling firm: Medtronic Vascular, Inc.; Status: Terminated; Reported quantity: ~1000; Lot: TBXXXXXXXXCP, TFXXXXXXXXCP, TWXXXXXXXXCP, TAXFXXXXXXXCP, TAXWXXXXXXXCP, VAMFXXXXXXXXTE, VAMCXXXXXXXXTE, VAMFXXXXXXXXTU, VAMCXXXXXXXXTU. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Firm received reports of difficulty in flushing the graft cover of the delivery system during device preparation as required by IFU.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Medtronic Vascular, Inc.
Distributor
International distribution:Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Iceland, Ireland, It lay, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom.
Lot
TBXXXXXXXXCP, TFXXXXXXXXCP, TWXXXXXXXXCP, TAXFXXXXXXXCP, TAXWXXXXXXXCP, VAMFXXXXXXXXTE, VAMCXXXXXXXXTE, VAMFXXXXXXXXTU, VAMCXXXXXXXXTU.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Valiant Thoracic Stent Graft with Captivia Delivery System, Talent Thoracic Stent Graft with the Captivia Delivery System. recalled?

Yes. FDA published recall Z-0083-2014 on November 6, 2013. Reported hazard: Firm received reports of difficulty in flushing the graft cover of the delivery system during device preparation as required by IFU.

What should I do if I have this product?

Voluntary: Firm initiated · Letter